MARKET

APOP

APOP

Cellect Bio
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.700
-0.090
-5.03%
After Hours: 1.700 0 0.00% 18:13 10/28 EDT
OPEN
1.820
PREV CLOSE
1.790
HIGH
1.820
LOW
1.650
VOLUME
59.02K
TURNOVER
--
52 WEEK HIGH
6.89
52 WEEK LOW
0.4000
MARKET CAP
6.65M
P/E (TTM)
--
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Cellect Biotechnology on go with ApoGraft initial-stage study for bone marrow transplantations
Cellect Biotechnology ([[APOP]] +0.2%) has commenced its second clinical trial in the US to evaluate the safety of the ApoGraft technology for bone marrow transplantations ((BMT)).  ApoGraft cell selection technology is designed
Seekingalpha · 6d ago
Cellect Biotechnology Initiates U.S. Clinical Trial of ApoGraft
Cellect Biotechnology Initiates U.S. Clinical Trial of ApoGraft Tel Aviv, Israel , Oct. 22, 2020 (GLOBE NEWSWIRE) -- Cellect Biotechnology Ltd. (NASDAQ: "APOP"), a developer of innovative technology which
Benzinga · 6d ago
Genfit, Evogene leads healthcare gainers, Rite Aid, Cellect Biotechnology among major losers
Gainers: Genfit (GNFT) +15%, Evogene (EVGN) +13%, Marinus Pharmaceuticals (MRNS) +11%, Endo International (ENDP) +8%, Happiness Biotech Group (HAPP) +7%.Losers: Rite Aid (RAD) -10%, Cellect Biotechnology (APOP) -8%, Kaleido Biosciences (KLDO) -7%, Taiwan Liposome (TLC) -6%, Nephros (NEPH) -6%.
Seekingalpha · 09/25 15:02
Owens & Minor, Kaleido Biosciences among major healthcare gainers, MediciNova, Rite Aid leads losers pack
Gainers: Owens & Minor (OMI) +53%, Kaleido Biosciences (KLDO) +39%, LogicBio Therapeutics (LOGC) +30%,  Cellect Biotechnology (APOP) +25%, Neuronetics (STIM) +6%.Losers: MediciNova (MNOV) -20%, Rite Aid (RAD) -17%, ADiTx Therapeutics (ADTX) -12%, NanoVibronix (NAOV) -12%, Rockwell Medical (RMTI) -10%.
Seekingalpha · 09/24 15:00
Cellect Biotechnology to Present at the 2020 Cell & Gene Meeting on the Mesa
Management to Highlight Progress in Bone Marrow Transplant (BMT) and Chimeric Antigen Receptor T Cell (CAR T) Business CollaborationsTel Aviv, Israel, Sept. 21, 2020 (GLOBE NEWSWIRE) --  Cellect Biotechnology Ltd. (NASDAQ: “APOP”), a developer of innovative technology which enables the functional selection
GlobeNewswire · 09/21 12:30
Cellect Bio nabs new patent in Europe
European Patent Office has granted Cellect Biotechnology (APOP +3.6%) a Patent Application no. 14851547.1 for Apograft, covering the activation of the stem
seekingalpha · 08/06 18:40
European Patent Office Grants Cellect Biotechnology Pivotal Patent for Stem Cells Activation
Cellect Biotechnology Ltd. (NASDAQ: APOP), a developer of innovative technology which enables the functional selection of stem cells, today announced that it has significantly strengthened its Intellectual Property (IP) portfolio as European Patent Application
PR Newswire · 08/06 12:30
Cellect Biotechnology Q1 EPS $(0.002) Up From $(0.008) YoY
Cellect Biotechnology (NASDAQ:APOP) reported quarterly losses of $(0.00) per share. This is a 75 percent increase over losses of $(0.01) per share from the same period last year.
Benzinga · 05/21 20:19
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Balance SheetMore
Cash FlowMore
OperatingInvestingFinancing
Learn about the latest financial forecast of APOP. Analyze the recent business situations of Cellect Bio through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average APOP stock price target is 12.00 with a high estimate of 12.00 and a low estimate of 12.00.
EPS
Institutional Holdings
Institutions: 13
Institutional Holdings: 848.18K
% Owned: 21.70%
Shares Outstanding: 3.91M
TypeInstitutionsShares
Increased
2
99.40K
New
2
7.67K
Decreased
0
0
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.24%
Pharmaceuticals & Medical Research
-2.11%
Key Executives
Chairman/Director
Nuriel Kasbian
Chief Executive Officer/Director
Shai Yarkoni
Chief Financial Officer
Eyal Leibovitz
Vice President - Research & Development
Amotz Nehushtan
Other
Yaron Pereg
Other
Guy Sapir
Director
Ruth Ben Yakar
Director
Michael Berelowitz
Non-Executive Director
Yuval Berman
Non-Executive Director
David Grossman
Independent Director
Abraham Nahmias
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About APOP
Cellect Biotechnology Ltd is an Israel-based biotechnology company. Its technology platform, ApoGraft, selects stem cells to improve the safety and efficacy of regenerative medicine and cell therapies by using functional selection. Efficient selection enables retention of most of the stem cells while neutralizing harmful mature cells. ApoGraft exploit a functional characteristic of stem cells relating to apoptosis, which is the process of programmed cell death and is a vital part of physiological development and homeostasis of all organisms. Stem cells flourish in an environment where normal cells die because their main role is reconstitution of damaged tissue. The platform is being tested for clinical use in allogeneic hematopoietic stem cell transplantation (HSCT) for the treatment of hematological malignancies. Additionally, the Company is developing its first product based on its platform, the ApoTainer selection kit that utilizes FasL-coated paramagnetic beads.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Cellect Biotechnology Ltd - ADR stock information, including NASDAQ:APOP real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, APOP stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading APOP stock methods without spending real money on the virtual paper trading platform.